Combining markers that help delineate sepsis and early AKI may prove a low-risk diagnostic test that decreases multisystem organ failure among the septic population. The role and clinical relevance of biomarkers, PCT for sepsis and [TIMP-2*IGFBP-7] for early AKI in this diagnostic and clinical scenario are discussed.

This session was organized by bioMérieux (http://www.biomerieux.com) and presented during the Society of Critical Care Medicine’s (SCCM) 2023 Critical Care Congress.

SCCM offers various sponsorship and advertising opportunities for industry partners to promote their brand launches or current therapies, conduct a focused program on disease awareness, or discuss their current pipeline activity.

The views and opinions expressed are those of the sponsor and do not necessarily reflect the views or opinions of SCCM. References to specific commercial entities, products, tests, procedures, opinions, resources, and information do not reflect SCCM’s review or endorsement.